Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATH-063 in biologic-relapsed/refractory moderate-to-severe ulcerative colitis
2024-520183-33-00Phase 2Authorised
- Sponsor
- Athos Therapeutics
- Start
- Sep 2026
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 2, randomised, double-blind trial in autoimmune colitis comparing ATH-063 with Placebo (2 arms). Primary endpoint: Clinical remission at Week 12. Planned start Sep 2026; status: authorised.
02
Drugs
ATH-063
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on 2024-520183-33-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-520183-33-00.